Leerink Partnrs Issues Optimistic Forecast for ASND Earnings

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Leerink Partnrs increased their Q1 2025 earnings per share estimates for Ascendis Pharma A/S in a report released on Wednesday, February 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($1.63) per share for the quarter, up from their prior forecast of ($1.90). The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.36) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S's Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at ($5.91) EPS and FY2026 earnings at ($2.28) EPS.

Several other brokerages have also issued reports on ASND. Evercore ISI boosted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday. Oppenheimer lowered their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $197.36.

Ascendis Pharma A/S Stock Performance

Shares of ASND traded down $1.08 during trading hours on Monday, reaching $155.11. 803,905 shares of the company traded hands, compared to its average volume of 517,463. The stock's fifty day moving average is $133.61 and its 200 day moving average is $132.72. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The stock has a market cap of $9.41 billion, a P/E ratio of -21.85 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. RA Capital Management L.P. grew its position in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after acquiring an additional 402,316 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 2.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after purchasing an additional 114,167 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after buying an additional 39,309 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.